Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 4,304 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 4,304 shares of Nurix Therapeutics stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total transaction of $51,691.04. Following the completion of the transaction, the chief financial officer owned 40,914 shares in the company, valued at approximately $491,377.14. This represents a 9.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Houte Hans Van also recently made the following trade(s):

• On Friday, May 2nd, Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX opened at $11.88 on Thursday. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56. The company has a market capitalization of $908.23 million, a PE ratio of -4.55 and a beta of 2.15. The firm’s 50-day moving average is $11.77 and its two-hundred day moving average is $13.18.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.27. The company had revenue of $44,056 billion for the quarter, compared to the consensus estimate of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. On average, analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on NRIX shares. Stifel Nicolaus dropped their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, April 9th. Morgan Stanley set a $16.00 price target on shares of Nurix Therapeutics and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Needham & Company LLC reiterated a “buy” rating and set a $27.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Wells Fargo & Company dropped their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 9th. Finally, UBS Group dropped their price target on shares of Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating on the stock in a research note on Thursday, July 10th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, Nurix Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $29.31.

Hedge Funds Weigh In On Nurix Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of NRIX. FMR LLC lifted its stake in shares of Nurix Therapeutics by 1,711.9% during the fourth quarter. FMR LLC now owns 10,634,231 shares of the company’s stock valued at $200,349,000 after buying an additional 10,047,329 shares during the period. RA Capital Management L.P. purchased a new position in Nurix Therapeutics during the fourth quarter worth approximately $25,120,000. Soleus Capital Management L.P. raised its stake in Nurix Therapeutics by 97.3% during the fourth quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company’s stock worth $39,617,000 after purchasing an additional 1,036,999 shares during the period. Point72 Asset Management L.P. purchased a new position in Nurix Therapeutics during the fourth quarter worth approximately $16,447,000. Finally, Vestal Point Capital LP raised its stake in Nurix Therapeutics by 132.1% during the first quarter. Vestal Point Capital LP now owns 1,125,552 shares of the company’s stock worth $13,372,000 after purchasing an additional 640,552 shares during the period.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.